Get the Stockscreener App
2.51
1.57%
-0.04
After Hours:
2.51
Fulcrum Therapeutics Inc stock is traded at $2.51, with a volume of 346.35K.
It is down -1.57% in the last 24 hours and down -23.24% over the past month.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
See More
Previous Close:
$2.55
Open:
$2.49
24h Volume:
346.35K
Relative Volume:
0.80
Market Cap:
$135.49M
Revenue:
$2.81M
Net Income/Loss:
$-97.34M
P/E Ratio:
-1.5886
EPS:
-1.58
Net Cash Flow:
$-91.47M
1W Performance:
-16.61%
1M Performance:
-23.24%
6M Performance:
-34.29%
1Y Performance:
-72.14%
1-Day Range:
$2.40
$2.565
1-Week Range:
$2.40
$3.01
52-Week Range:
$2.40
$10.13
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Name
Fulcrum Therapeutics Inc
Sector
Industry
Phone
617-651-8851
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare FULC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
2.51 | 135.49M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-12-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-12-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-12-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-12-24 | Downgrade | Stifel | Buy → Hold |
| Sep-09-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Sep-25-23 | Initiated | Goldman | Neutral |
| Aug-23-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Aug-22-23 | Upgrade | Stifel | Hold → Buy |
| May-04-23 | Downgrade | Goldman | Buy → Neutral |
| Mar-10-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-10-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-09-23 | Downgrade | Stifel | Buy → Hold |
| Feb-28-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-24-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-15-22 | Initiated | Goldman | Buy |
| Mar-08-22 | Initiated | Oppenheimer | Outperform |
| Mar-03-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-11-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-22-21 | Initiated | Credit Suisse | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Oct-16-20 | Initiated | Piper Sandler | Overweight |
| Aug-12-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-12-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-12-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-19-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Oct-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-12-19 | Initiated | BofA/Merrill | Buy |
View All
Fulcrum Therapeutics Inc Stock (FULC) Latest News
Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Business And Shares Still Trailing The Industry - simplywall.st
Fulcrum Therapeutics stock hits 52-week low at $2.77 - Investing.com India
Charles Schwab Investment Management Inc. Lowers Stock Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Brokerages Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Price Target at $8.63 - Defense World
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Fulcrum Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FULC - Business Wire
Fulcrum Therapeutics stock hits 52-week low at $2.85 By Investing.com - Investing.com Australia
Fulcrum Therapeutics stock hits 52-week low at $2.85 - Investing.com India
Fulcrum Therapeutics at Leerink’s Global Healthcare Conference: Strategic Insights By Investing.com - Investing.com UK
Investors who lost money on Fulcrum Therapeutics, Inc. should contact Levi & Korsinsky about an ongoing investigationFULC - ACCESS Newswire
Bristol Myers Acquired MyoKardia Drops Fulcrum Agreement, Ending Cardiomyopathy Research Deal - Benzinga
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference - The Manila Times
Fulcrum Therapeutics Ends Agreement with MyoKardia By Investing.com - Investing.com South Africa
Fulcrum Therapeutics Ends Agreement with MyoKardia - Investing.com India
Fulcrum Therapeutics Faces Termination of Key Agreement - TipRanks
Fulcrum Therapeutics Inc Myokardia Terminates Collaboration And License Agreement With Co - Marketscreener.com
Will Fulcrum Therapeutics Reveal New Rare Disease Pipeline Updates at Upcoming Leerink Conference? - StockTitan
Fulcrum Therapeutics (NASDAQ:FULC) Issues Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Leerink Partnrs Issues Negative Forecast for FULC Earnings - Defense World
HC Wainwright Has Pessimistic Outlook of FULC Q1 Earnings - Defense World
Fulcrum Therapeutics’ (FULC) Neutral Rating Reiterated at HC Wainwright - Defense World
Fulcrum Therapeutics' (FULC) Neutral Rating Reiterated at HC Wainwright - MarketBeat
Levi & Korsinsky Announces an Investigation on Behalf of Fulcrum Therapeutics, Inc. (FULC) Shareholders Who May Have Been Affected by Fraud - ACCESS Newswire
What is HC Wainwright's Forecast for FULC FY2029 Earnings? - MarketBeat
FY2029 Earnings Estimate for FULC Issued By HC Wainwright - Defense World
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Average Rating of “Hold” from Brokerages - Defense World
Fulcrum Therapeutics’ Earnings Call Highlights Financial Gains - TipRanks
Shareholder Rights Advocates at Levi & Korsinsky Investigate Fulcrum Therapeutics, Inc. (FULC) Regarding Possible Securities Fraud Violations - ACCESS Newswire
Shareholders that lost money on Fulcrum Therapeutics, Inc. (FULC) should contact Levi & Korsinsky about Securities Fraud InvestigationFULC - ACCESS Newswire
Fulcrum Therapeutics (NASDAQ:FULC investor five-year losses grow to 82% as the stock sheds US$28m this past week - Simply Wall St
Lost Money on Fulcrum Therapeutics, Inc.(FULC)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2024 Earnings Call Transcript - Insider Monkey
Fulcrum Therapeutics Inc (FULC) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Earnings To Watch: Fulcrum Therapeutics Inc (FULC) Reports Q4 20 - GuruFocus.com
Fulcrum Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
FULCRUM THERAPEUTICS Earnings Results: $FULC Reports Quarterly Earnings - Nasdaq
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024 - The Manila Times
Fulcrum Therapeutics, Inc. SEC 10-K Report - TradingView
Fulcrum Therapeutics Reports Q4 and Full Year 2024 Financial Results and Updates on Pioneering SCD Trial - Nasdaq
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth - The Bakersfield Californian
Can Fulcrum's Improved Financials and Sickle Cell Trial Progress Attract Biotech Investors? - StockTitan
Earnings To Watch: Fulcrum Therapeutics Inc (FULC) Reports Q4 2024 Result - Yahoo Finance
Fulcrum Therapeutics (FULC) to Release Quarterly Earnings on Tuesday - Defense World
Fulcrum Therapeutics, Inc. Being Investigated on Behalf of Fulcrum Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details. - ACCESS Newswire
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Short Interest Down 7.3% in January - MarketBeat
Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET - The Manila Times
Fulcrum Therapeutics, Inc. Scheduled to Release Q4 and Full Year 2024 Financial Results on February 25, 2025 - Nasdaq
Rare Disease Pioneer Fulcrum Sets Stage for Major 2024 Financial Revelation - StockTitan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulcrum Therapeutics, Inc. (FULC) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fulcrum: Next Set Of SCD Data Is Crucial For Continued Pipeline Advancement - Seeking Alpha
Fulcrum Therapeutics Inc Stock (FULC) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):